What's in Eiger BioPharmaceuticals's pipeline?

Eiger BioPharmaceuticals has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Eiger BioPharmaceuticals's portfolio?

Top competitors by shared drug class: Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/eiger-biopharmaceuticals.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Eiger BioPharmaceuticals — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eiger BioPharmaceuticals pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Placebo Lonafarnib	Placebo Lonafarnib	phase 3	Farnesyltransferase inhibitor	Farnesyltransferase	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Eiger BioPharmaceuticals:

Cite this brief

Drug Landscape (2026). Eiger BioPharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eiger-biopharmaceuticals. Accessed 2026-05-17.